Miki Takemura

906 total citations
34 papers, 707 citations indexed

About

Miki Takemura is a scholar working on Molecular Medicine, Pharmacology and Applied Microbiology and Biotechnology. According to data from OpenAlex, Miki Takemura has authored 34 papers receiving a total of 707 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Medicine, 25 papers in Pharmacology and 11 papers in Applied Microbiology and Biotechnology. Recurrent topics in Miki Takemura's work include Antibiotic Resistance in Bacteria (29 papers), Antibiotics Pharmacokinetics and Efficacy (25 papers) and Antibiotic Use and Resistance (11 papers). Miki Takemura is often cited by papers focused on Antibiotic Resistance in Bacteria (29 papers), Antibiotics Pharmacokinetics and Efficacy (25 papers) and Antibiotic Use and Resistance (11 papers). Miki Takemura collaborates with scholars based in Japan, United States and Taiwan. Miki Takemura's co-authors include Yoshinori Yamano, Rio Nakamura, Shuhei Matsumoto, Shinsuke Toba, Masakatsu Tsuji, Takafumi Sato, Naoki Ishibashi, Naoki Kohira, Roger Echols and Toru Nishikawa and has published in prestigious journals such as Journal of Clinical Microbiology, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Miki Takemura

34 papers receiving 698 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Miki Takemura Japan	12	592	432	204	149	130	34	707
Naoki Kohira Japan	8	681 1.2×	475 1.1×	188 0.9×	199 1.3×	167 1.3×	12	830
Henrietta Abodakpi United States	10	497 0.8×	353 0.8×	193 0.9×	79 0.5×	160 1.2×	12	563
Tsukasa Ito-Horiyama Japan	4	450 0.8×	362 0.8×	146 0.7×	77 0.5×	115 0.9×	6	518
Justin R. Lenhard United States	16	527 0.9×	365 0.8×	130 0.6×	172 1.2×	174 1.3×	29	735
Concepción Segura Spain	10	442 0.7×	269 0.6×	93 0.5×	93 0.6×	183 1.4×	12	556
Melissa D. Barnes United States	16	777 1.3×	490 1.1×	193 0.9×	182 1.2×	255 2.0×	22	928
Christian M Gill United States	13	428 0.7×	231 0.5×	187 0.9×	106 0.7×	109 0.8×	48	537
Ester del Barrio-Tofiño Spain	7	523 0.9×	165 0.4×	134 0.7×	270 1.8×	80 0.6×	13	573
Anna Vickers United Kingdom	15	512 0.9×	328 0.8×	190 0.9×	146 1.0×	199 1.5×	23	699
Kai‐Tai Chang United States	15	402 0.7×	320 0.7×	147 0.7×	116 0.8×	155 1.2×	20	560

Countries citing papers authored by Miki Takemura

Since Specialization

Citations

This map shows the geographic impact of Miki Takemura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miki Takemura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miki Takemura more than expected).

Fields of papers citing papers by Miki Takemura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miki Takemura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miki Takemura. The network helps show where Miki Takemura may publish in the future.

Co-authorship network of co-authors of Miki Takemura

This figure shows the co-authorship network connecting the top 25 collaborators of Miki Takemura. A scholar is included among the top collaborators of Miki Takemura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miki Takemura. Miki Takemura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

DeJonge, Boudewijn L, et al.. (2025). The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method. Journal of Clinical Microbiology. 63(9). e0047125–e0047125. 1 indexed citations

Gill, Christian M, Miki Takemura, Christopher Longshaw, et al.. (2023). In vivoefficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versusAcinetobacter baumannii. Journal of Antimicrobial Chemotherapy. 78(4). 983–990. 20 indexed citations

Takemura, Miki, Mark G. Wise, Meredith Hackel, Daniel F. Sahm, & Yoshinori Yamano. (2023). In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014–2019). Journal of Antimicrobial Chemotherapy. 78(8). 2019–2027. 18 indexed citations

Wise, Mark G., James A. Karlowsky, Meredith Hackel, et al.. (2023). In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019. Microbial Drug Resistance. 29(8). 360–370. 21 indexed citations

DeJonge, Boudewijn L, Sean Nguyen, Joshua Maher, et al.. (2023). 2761. Activity of Cefiderocol and Comparator Agents Against Achromobacter and Burkholderia Isolates, Collected During 2020-2022 as Part of SENTRY Antimicrobial Surveillance Program. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Takemura, Miki, Rio Nakamura, Ryuichiro Nakai, et al.. (2023). In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. Antimicrobial Agents and Chemotherapy. 67(12). e0034623–e0034623. 5 indexed citations

Nordmann, Patrice, Ryan K. Shields, Yohei Doi, et al.. (2022). Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials. Microbial Drug Resistance. 28(4). 398–407. 53 indexed citations

Kohira, Naoki, Meredith Hackel, Miki Takemura, et al.. (2022). In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020. Journal of Global Antimicrobial Resistance. 32. 181–186. 3 indexed citations

Matuschek, Erika, Christopher Longshaw, Miki Takemura, Yoshinori Yamano, & Gunnar Kahlmeter. (2022). Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing. Journal of Antimicrobial Chemotherapy. 77(6). 1662–1669. 45 indexed citations

10.

Yamano, Yoshinori, et al.. (2021). 1287. Double Disk Diffusion Study to Evaluate the Synergistic Effect Between Cefiderocol and Ceftazidime-Avibactam Against Cefiderocol-Non-susceptible Acinetobacter baumannii. Open Forum Infectious Diseases. 8(Supplement_1). S732–S733. 1 indexed citations

11.

Yamano, Yoshinori, et al.. (2021). Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan. Journal of Global Antimicrobial Resistance. 28. 120–124. 30 indexed citations

12.

Takemura, Miki, et al.. (2021). 1106. Evaluation of Penetration of Cefiderocol into Cerebrospinal Fluid Using a Rat Meningitis Model. Open Forum Infectious Diseases. 8(Supplement_1). S645–S645. 8 indexed citations

13.

Yamano, Yoshinori, Miki Takemura, Christopher Longshaw, & Roger Echols. (2020). 1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol. Open Forum Infectious Diseases. 7(Supplement_1). S651–S651. 7 indexed citations

14.

Takemura, Miki, Krystyna M. Kazmierczak, Meredith Hackel, et al.. (2020). 1252. In Vitro Activity of Cefiderocol Against Metallo-β-Lactamase-Producing Gram-Negative Bacteria Collected in North America and Europe Between 2014 and 2017: SIDERO-WT-2014–2016 Studies. Open Forum Infectious Diseases. 7(Supplement_1). S643–S644. 3 indexed citations

15.

Matsunaga, Yuko, Mari Ariyasu, Miki Takemura, et al.. (2020). 165. Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study. Open Forum Infectious Diseases. 7(Supplement_1). S212–S212. 3 indexed citations

16.

Matsui, Kouhei, Yukiko Kan, Junko Kikuchi, et al.. (2020). Stalobacin: Discovery of Novel Lipopeptide Antibiotics with Potent Antibacterial Activity against Multidrug-Resistant Bacteria. Journal of Medicinal Chemistry. 63(11). 6090–6095. 17 indexed citations

17.

Yamano, Yoshinori, Rio Nakamura, Miki Takemura, & Roger Echols. (2020). 1455. Potential Mechanisms of Cefiderocol MIC Increase in Enterobacterales in In Vitro Resistance Acquisition Studies. Open Forum Infectious Diseases. 7(Supplement_1). S730–S730. 11 indexed citations

18.

Takemura, Miki, Yoshinori Yamano, Yuko Matsunaga, et al.. (2020). 1266. Characterization of Shifts in Minimum Inhibitory Concentrations During Treatment with Cefiderocol or Comparators in the Phase 3 CREDIBLE-CR and APEKS-NP Studies. Open Forum Infectious Diseases. 7(Supplement_1). S649–S650. 9 indexed citations

19.

Suzuki, Chiaki, et al.. (2017). Effects of Valsalva Maneuver by Different Breath-holding Techniques to Detect Pulmonary Thromboembolism in a Contrast-enhanced Computed Tomography Examination. Japanese Journal of Radiological Technology. 73(4). 273–281. 1 indexed citations

20.

Ito, Akinobu, Takafumi Sato, Miki Takemura, et al.. (2017). In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy. 62(1). 291 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact